PDF, Patent Landscape Report on Atazanavir - WIPO

PROTEASE INHIBITOR BREAK-THROUGHIn Figure 31, the Roche citation map for its protease inhibitor patent is arranged to show 1 stto 3 rd generation citations according to their year of publication. In the first few years,citation was at a low frequency because the original document was still in the early stagesof being noticed. The rate of citation then picked up speed, with an average rate of 280references per year since 2000. The arrow points out the founder patent for the Novartisdrug Atazanavir, which is within the 1998 branch of the map, and this branch is expanded inthe view below. Along with ATZ, many of the drugs later approved for inhibition of HIVprotease referred to the original Roche patent, and are therefore included among the citingreferences in this cite map.Figure 31. Citation Map of Roche’s Early HIV Protease Invention36